If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
Blanton Eye Institute, Houston Methodist Hospital, Houston, Tex.;Weill Cornell Medicine, New York, NY;University of Texas Medical Branch, Galveston, Tex.;University of Texas MD Anderson Cancer Center, Houston, Tex.;Texas A&M College of Medicine, Bryan, Tex.;University of Iowa Hospitals and Clinics, Iowa City, Iowa;
Isolated ADOA typically manifests in the first 2 decades of life as bilateral painless progressive vision loss and is therefore mostly diagnosed in childhood to young adulthood. We present a series of 2 older patients, aged 63 and 64 years, who had delayed ADOA diagnosis as proband patients in their families, emphasizing the point that chronological age should not be the sole determining factor for ordering testing for ADOA in cases of unexplained optic neuropathy.
Patient 1, a 64-year-old Caucasian man, was referred to the neuro-ophthalmology clinic with a 12-year history of isolated, unexplained bilateral painless progressive central vision loss. His past medical history was significant for type II diabetes mellitus, hyperlipidemia, obesity, obstructive sleep apnea, and ocular hypertension. His regular medications were Aspirin, atorvastatin, fenofibrate, metformin, montelukast, omeprazole, latanoprost, and sertraline. He did not smoke cigarettes or drink alcohol and reported a balanced diet. His family history was significant for an 11-year-old granddaughter who had recently been diagnosed with optic nerve hypoplasia.
The patient initially presented with painless bilateral slowly progressive vision loss 12 years prior. An initial diagnosis of cataracts was made with visual acuity of 20/100 OD and 20/80 OS and an otherwise normal eye examination. He underwent bilateral cataract extraction and intraocular lens implantation without improvement. Subsequent evaluation revealed an elevated intraocular pressure of up to 25 mm Hg, gonioscopy showing Shaffer grade 4 open angles, a cup-to-disc ratio of 0.3, and otherwise normal optic discs OU. He was treated with latanoprost for presumed glaucoma. In total, he saw 4 different ophthalmologists over 12 years. Optic atrophy was noted only in the records, 10 years after symptom onset, but it is likely that this ophthalmoscopic finding was present earlier in the course. The patient was referred to neuro-ophthalmology 12 years after initial presentation because the optic disc did not appear to be typically glaucomatous and because of central vision loss.
On neuro-ophthalmologic examination, the patient’s visual acuity was 20/40 OU. His pupils were isocoric without a relative afferent pupillary defect. Colour vision on Ishihara testing was 14/14 OU. Intraocular pressures were 17mm Hg OD and 19mm Hg OS. Dilated fundus examination showed optic disc pallor temporally OU, with a cup-to-disc ratio of 0.5 OD and 0.4 OS. The remainder of the eye and neurologic examinations was normal. Automated perimetry (Humphrey visual field 24-2) showed an enlarged blind spot and superior paracentral visual field defect, with a mean deviation of –3.55dB OS, and a temporal visual field defect superiorly, with a mean deviation of –3.53dB OD. Optical coherence tomography (OCT) showed average retinal nerve fibre layer (RNFL) of 64µm OD and 65µm OS, with primarily papillomacular bundle loss OU (Fig. 1). The OCT macular ganglion cell layer showed diffuse thinning.
The work-up for optic atrophy included magnetic resonance imaging of the brain and orbits with contrast material and was unremarkable. Laboratory studies, including complete blood count; determinations of sedimentation rate and C-reactive protein, folate, and angiotensin-converting enzyme levels; syphilis serology; and myelin oligodendrocyte glycoprotein testing, were unremarkable. Serum homocysteine was elevated at 14.9 µmol/L (normal <11.4 µmol/L), and the patient’s B12 level was low normal at 366 pg/mL (normal, 200–1100 pg/mL). Genetic testing revealed a pathogenic heterozygous frameshift mutation in the OPA1 gene, with a c.2708_2711:4 base pair deletion at codons 903–904. The diagnosis of ADOA was made, and the patient’s granddaughter with previously known optic nerve head abnormalities was also confirmed to have the same genetic diagnosis. Further family genetic counselling was recommended.
Patient 2, a 63-year-old Caucasian woman, presented to the neuro-ophthalmology clinic with a 10-year history of painless progressive vision loss OU and a diagnosis of idiopathic optic atrophy. Her past medical history was significant for hypothyroidism, hyperlipidemia, and excision of a T7 World Health Organization grade 1 spinal meningioma. Her regular medications included levothyroxine and rosuvastatin. Her family history was significant for a recent diagnosis of idiopathic optic atrophy in her daughter. When the patient initially presented 10 years prior, the neuro-ophthalmic evaluation was significant for bilateral optic atrophy and bilateral epiretinal membranes. External investigations were performed with magnetic resonance imaging of the brain and orbits with contrast material; complete blood count; determinations of serum vitamin B12, folate, and antinuclear antibodies; chest x-ray; and determinations of anti–aquaporin 4 antibodies and myelin oligodendrocyte glycoprotein antibodies returning negative. A multifocal electroretinogram was within normal limits in the setting of the known epiretinal membranes. The patient presented to a second neuro-ophthalmologist for further evaluation.
On examination, the patient’s visual acuity was 20/40 OD and 20/30 OS. Her pupils were isocoric without a relative afferent pupillary defect. Intraocular pressures were normal. Slit-lamp examination was significant only for mild nuclear sclerotic cataracts OU. Colour vision was 1/14 on the Ishihara test OU. Dilated fundus examination showed optic disc pallor temporally OU, with a cup-to-disk ratio of 0.4 OU. The remainder of her eye and neurologic examinations was normal. Humphrey visual field 24-2 showed nonspecific abnormalities OU, with a mean deviation of –4.52dB OD and –3.32dB OS. OCT showed a reduced average retinal nerve fibre layer thickness of 71µm OD and 58µm OS, with primarily papillomacular bundle loss OU. OCT of the macula showed bilateral epiretinal membranes with intraretinal cysts OD and average macula thickness of 415µm OD and 253µm OS (Fig. 2). OPA1 testing was performed and revealed a pathogenic heterozygous frameshift mutation, a c.2708_2711:4 base pair deletion at codons 903–904. The diagnosis of ADOA was confirmed, and recommendations were made for the patient’s family members to also undergo testing for the OPA1 mutation.
The typical age of presentation with reduced visual acuity in ADOA is commonly reported as being in the first 2 decades of life, with large studies across the world reporting ages between 4 and 10 years and a large meta-analysis reporting that 85% of patients with ADOA had symptom onset at <20 years of age.
However, variable expressivity is well reported in the literature and identified commonly in mutation screening of affected family members—23% of patients in a report of 30 patients did not have clinical optic atrophy even when examined with a known diagnosis.
Whether the age of onset of clinical symptoms affects the level of visual function is also not clearly known. In part, the possibility of patients with gradual vision loss not recognizing the symptoms until they are more severe and therefore having a delayed presentation or never presenting to medical attention could be a consideration. Further, it is suggested that deletions, nonsense, and splice-site mutations may offer a better visual outcome than missense mutations, and both our patients had the same deletion mutation.
However, severe visual symptoms have been reported with older age at presentation—1 patient with ADOA plus (a proband in her family) had visual symptoms first in her 40s and was legally blind in her 70s.
Longitudinal studies looking at visual progression do not typically report findings of asymptomatic patients as much as they do symptomatic patients, but one such study of ADOA reported that 11 of 69 patients were identified with OPA1 mutations who reported being asymptomatic—although their ages were not recorded in the published results, the mean best-corrected visual acuity reported was 6/5.7 (20/19).
Older patients (>40 years old with a mean age of 59.4 years) in this study (both symptomatic and asymptomatic) were noted overall to have a worse visual acuity of 6/23.3 versus 6/12.9 in patients under age 40 years, although the age of onset of disease in these patients is unclear.
Another reported Australian family noted that 6 of the 8 family members manifested only visual symptoms in their fourth to fifth decades of life, again highlighting the variability in age of clinical presentation of OPA1 mutation.
The oldest reported age at diagnosis of ADOA was 62 years in a woman who also underwent multiple investigations and treatments, including a temporal artery biopsy and intravenous steroids, although this patient had a number of atypical features, including rapid-onset unilateral vision loss and optic disc edema, with a contralateral episode 9 months later.
In a study looking at affected OPA1 mutation patients and mutation-free family members, there was a significant thinning of both the RNFL and the ganglion cell layer in affected patients, which was noted even in the youngest patient (8 years of age), suggesting that the structural deficit occurs at a young age.
Other studies have noted that thinning of the RNFL over time is similar in patients with OPA1 mutations and control patients, although the absolute RNFL thickness is less in OPA1 mutation patients, also suggesting early onset of structural abnormalities in these patients.
Specific OCT analysis in asymptomatic populations has not been well reported.
In summary, we describe 2 patients with a delayed diagnosis of ADOA, both aged in their 60s, who were probands for their families and led to diagnoses in their younger family members. Both our patients, in retrospect, had many features that made the diagnosis of hereditary optic neuropathy much more likely, including family histories of vision loss in younger generations, loss of visual acuity, temporal pallor on fundus examination, and papillomacular bundle loss on OCT, and 1 patient also had significant colour vision abnormalities. In both cases, however, our patients became the proband diagnosis for OPA1 mutation, and it was their positive result that led to recommendations for testing in other family members with visual symptoms. Both our patients underwent multiple investigations and treatment trials, including cataract surgery, prior to the diagnosis.
Clinicians should be aware of the possibility of ADOA as a clinically manifest disease in later life, prompting appropriate molecular diagnosis and possible genetic counselling in an otherwise untreatable condition.
Footnotes and Disclosure
The authors have no proprietary or commercial interest in any materials discussed in this correspondence.